Philadelphia Pharmaceuticals Co.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: JO4121911013
JOD
1.55
-0.02 (-1.27%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Philadelphia Pharmaceuticals Co. stock-summary
stock-summary
Philadelphia Pharmaceuticals Co.
Pharmaceuticals & Biotechnology
Philadelphia Pharmaceuticals Industry Company PSC is a Jordan-based company that is engaged in the development, manufacture and marketing of human pharmaceutical products of different therapeutic categories. The Company, through its production facilities and laboratories located in Amman Industrial state, develops and produces a number of products that includes: Semisolid Dosage Forms, such as creams, ointments, lotions, gels and suppositories, as well as Liquid Dosage Forms, which include syrups, suspensions, solutions, nasal, drops, mouth washes and vaginal douches. Furthermore, the Company undertakes the distribution and marketing of a range of healthcare systems, miscellaneous and pharmaceuticals of different international brand names, including alimentary, gastrointestinal systems and respiratory systems. The Company markets its products to the local markets and exports to more than 10 countries in the Middle East and North Africa region.
Company Coordinates stock-summary
Company Details
Str 10,Shb Kng Abdlh Ibn Al Hn 2 Ind Cty, Street 10, King Abdullah 2 Indstl City, P.O.Box 276, AMMAN None : 11512
stock-summary
Tel: 962 6 4029181
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
Mondher Hussein
Chairman of the Board
Kayed Al Shaabani
Vice Chairman of the Board
Khader Jarwan
General Manager, Secretary, Member of the Board
Ridha Al Ghoul
Member of the Board
Gabriel Kleis
Member of the Board
Mohammed Sayyan
Member of the Board
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
2 Million
(Quarterly Results - Jun 2025)
Net Profit:
0 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

JOD Million (Small Cap)

stock-summary
P/E

0

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.03

stock-summary
Return on Equity

6.93%

stock-summary
Price to Book

0.00